Principal Researcher, Biologist


Maria Paravatou received her BSc in biology from the department of Mathematical Physics, Aristotle University of Thessaloniki (1978), her MSc in Genetics (1982) and her PhD (1984) degrees from the University of Paris VII, Jussieu.

Presently she is a senior researcher in the field or Radiobiology at the National Centre of Scientific Research “Demokritos”, (NCSR “D”). She has worked as a Post-doctoral fellow (1984) in Radiobiology at the Institut Curie, Section Biologie, Laboratoire du CNRS URA 620, Structure et Μutagenèse Chromosomique, Paris, France, and from 1993 to 1997, as an associated researcher in Human Genetics, at the Università Cattolica del Sacro Cuore, Facoltà di Medicina, Istituto di Genetica Medica, Roma, Italia.

Her research interests have been mainly focused in: (1) the study of chromosomal aberrations induced by ionizing radiation, found in human pathology or in the evolution of the primates (2) human genetic studies (3) toxicological studies on biological systems of environmental or synthetic chemicals, and biological studies on new drugs and nanopartical.and (4) the radiosensitivity induced by various drugs in biological systems

She is lecturing from 2012 at the Inter-University post-graduate course in “Medical Physics – Radiophysics” the course “Biology” and, from 2010 at the Dpt. οf Biology, National and Kapodistrian University of Athens, Applications of Biology in Health in the course “Ionizing radiation and health”

Selected Publications

Selected Grants

COST Action CA19114: Network for Optimized Astatine labeled Radiopharmaceuticals

2020-2024 | European Cooperation in Science and Technology (COST)

The purpose of the COST Action CA19114 entitled "Network for Optimized Astatine-labeled Radiopharmaceuticals" (NOAR) is to create a network of scientists to investigate the production conditions of the α-particle emitter Astatine-211 (Astatine-211: 211At) and its application in Targeted A...


COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside"

2018-2022 | European Cooperation in Science and Technology (COST)

The COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside" focuses on the development of nanosystems transporting anti-cancer drugs. The pan-European network of specialists from universities, research centers, clinical research organizations and companies is ...


Dual-targeting iron oxide nanoparticles against bombesin receptors (BNRs) and Prostate Specific Membrane Antigen (PSMA), radiolabeled with Gallium-68, as PET/MRI imaging agents for prostate cancer

2020-2021 | ΕΣΠΑ/Εκπαίδευση και Δια Βίου Μάθηση

The present research project is focused on the development of iron oxide nanoparticles (IONPs) radiolabeled with 68Ga, for dual-modality molecular imaging of prostate cancer with PET/MRI. These NPs are functionalized with adequate pharmacophores (peptides or peptidomimetic molecules) so a...

INRASTES - Official Web Site
Skip to content